Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial

[1] Melton LJ(1993)Hip fractures: a worldwide problem today and tomorrow Bone 14 S1-S8

[2] Black DM(2000)Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial J Clin Endocrinol Metab 85 4118-4124

[3] Black DM(1996)Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535-1541

[4] Cummings SR(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial Jama 280 2077-2082

[5] Johnell O(2003)Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures Pharmacoeconomics 21 305-314

[6] Jonsson L(2003)[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial] Ugeskr Laeger 165 4112-4116

[7] Borgstrom F(1998)Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis Pharmacoeconomics 14 559-573

[8] Zethraeus N(2003)[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective] Lakartidningen 100 36-40

[9] Rosner AJ(1997)Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women Am J Med 103 291-297

[10] Borgstrom F(2002)Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 137 875-883

[1] Melton LJ(1993)Hip fractures: a worldwide problem today and tomorrow Bone 14 S1-S8

[2] Black DM(2000)Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial J Clin Endocrinol Metab 85 4118-4124

[3] Black DM(1996)Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535-1541

[4] Cummings SR(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial Jama 280 2077-2082

[5] Johnell O(2003)Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures Pharmacoeconomics 21 305-314

[6] Jonsson L(2003)[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the fracture intervention trial] Ugeskr Laeger 165 4112-4116

[7] Borgstrom F(1998)Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis Pharmacoeconomics 14 559-573

[8] Zethraeus N(2003)[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective] Lakartidningen 100 36-40

[9] Rosner AJ(1997)Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women Am J Med 103 291-297

[10] Borgstrom F(2002)Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 137 875-883